Rosetta Genomics to Raise $2.2M in Direct Offering | GenomeWeb

Rosetta Genomics to Raise $2.2M in Direct Offering

May 17, 2012

|

a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Rosetta Genomics today said that it has entered into definitive agreements with investors to purchase $2.2 million worth of its stock.

Under the registered direct offering, the firm will sell 632,057 ordinary shares at $3.50 per share. The offering is expected to close on or around May 22.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Related Articles

Jan 29, 2015

Biofortuna Closes $2.2M Funding Round

Oct 15, 2014

NextGxDx Adds $2.2M to Series B Financing

Apr 03, 2014

BG Medicine Prices Public Offering, Anticipates $8.9M in Net Proceeds

Mar 11, 2014

European Researchers Launch $2.2M Project to Develop Sepsis Test

Mar 28, 2014

Jackson Lab Team Lands $2.2M for Noncoding RNA Studies

Aug 22, 2014

NeoGenomics Closes $34.6M Public Offering

Breaking News

The Scan

This Week in PLOS

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

Things Not Found

With a new collection, PLOS highlights negative results it has published.

Is the Sequencer Half Full or Half Empty?

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

Packs a Punch

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

Featured White Papers

Miniaturizing siRNA Transfection Using the Echo Liquid Handler

RNAi Screening in Primary Cells